Search

BACKGROUND AND OBJECTIVES Antibodies to hepatitis B core antigen (anti-HBc) testing were added to hepatitis surface antigen (HBsAg) screening in Germany in 2006 to prevent hepatitis B virus (HBV) transmissions by chronically infected donors. We report the results of a national surveillance of anti-HBc-reactive and HBsAg-negative donations and assess the resulting gain in blood safety and the donor loss. MATERIALS AND METHODS Donations were tested for anti-HBc, and if reactive, by sensitive individual donation nucleic acid testing (ID-NAT) and for antibodies to HBsAg (anti-HBs). Data from the national anti-HBc surveillance from 2006 to 2015 determined the proportion of anti-HBc-reactive donations stratified for donor type, sex, anti-HBs concentration and NAT-positivity. Donor loss due to anti-HBc-reactive results was quantified. RESULTS Of 31 562 556 donations screened, 70 671 were anti-HBc reactive but HBsAg negative (0.22%). The proportion of repeat donors with these test results decreased significantly from 0.25% in 2007 to 0.08% in 2015. In the entire study period, 82 HBV-NAT-positive donations were identified. Of these, 47 donations were only identified by ID-NAT. A total of 54 203 anti-HBc-reactive units were discarded either due to possible infectiousness (NAT positive or anti-HBs concentration

Background and Objectives The Korean Red Cross began nucleic acid amplification testing (NAT) for HIV and HCV in February 2005, and added HBV NAT beginning in June 2012. The current NAT system utilizes a multiplex assay for simultaneous detection of HBV DNA, HCV RNA and HIV-1 RNA. For samples that are reactive in the multiplex assay, we do specific tests for each virus. However, there have been cases of non-discriminated reactive (NDR) results which appear to be the result of non-specific reactions or cross-contamination, although some cases are considered to arise from the presence of low levels of HBV DNA due to occult hepatitis B infection. Materials and Methods We examined the incidence of NDR results in previous donations of some NAT-reactive donors. Additionally, for those donors with NDR results, we performed an HBV core antibody (anti-HBc) assay. Results From November 2015 to March 2016, there were 408 NAT-reactive donors. Of these, nineteen HBV NAT-reactive donors showed a history of NDR results in the past donations. Seven donors showed NDR results more than once. Of 771 NDR donors, 362 (47·0%) were anti-HBc reactive. Conclusion The NDR donors had a substantially higher rate of anti-HBc reactivity than other blood donors indicating that some with anti-HBc reactivity represent donors with occult HBV. Therefore, the incorporation of an anti-HBc testing for NDR donors could improve blood safety testing for the Korean Red Cross.

H. W. Reesink, C. P. Engelfriet, G. Henn, W. R. Mayr, G. Delage, F. Bernier, T. Krusius, A. Assal, P. Gallian, C. Corbi, P. Morel, B. David, P. De Micco, H. Murokawa, H. Yugi, S. Hino, K. Tadokoro, O. Flesland, E. Brojer, M. Oe towska, G. Olim, F. Nascimento, H. Goncalves, L. Castro, M. Morais, S. L. Stezinar, M. Alvarez, S. Sauleda, R. Gonzalez, C. Niederhauser, M. Stolz, J.-P. Allain, S. Owusu-Ofori, R. Eglin, S. Stramer, M. Busch, D. M. Strong, J. Epstein, R. Biswas

The International Society of Blood Transfusion (ISBT) transfusion-transmitted infections (TTI) working party is proposing to undertake an international collaborative study aimed at understanding occult hepatitis B infection by molecular and immunological characterization, determining infectivity by transfusion and clinical relevance of this newly identified condition. This article provides information to the transfusion community and aims to recruit potential collaborators for the study. Further information can be obtained from the author or the ISBT TTI working group website (http://www.isbt-web.org).

Background and objectives: To determine whether antibody to hepatitis B core (anti-HBc) reactivity, as a marker of hepatitis B virus infection, reflects a ‘lifestyle’ risk in donors in North London, we have obtained detailed histories from donors with various manifestations of HBV infection. Materials and methods: Interviews based on a standardised questionnaire were conducted with 70 donors confirmed to be anti-HBc reactive. Results: Comparison with controls (known to be anti-HBc-negative) and donors reactive for anti-hepatitis-C virus showed that current donor strategies are effective; in our area, reactivity for anti-HBc is not associated with a lifestyle risk for those donors who are unreactive in current mandatory screening tests. Conclusions: Blood from donors positive for both anti-HBc and anti-HBs should be considered suitable for transfusion purposes. This is consistent with the practice of accepting blood from naturally immune donors for preparation of hepatitis B immunoglobulin.